Poseida Therapeutics (PSTX) Event June 16, 2022, 21:30 UTC (99% Neutral) Poseida Therapeutics, Inc. (PSTX) Announces Regulatory Update Full text
Register to leave comments News bot Oct. 2, 2025, 8 a.m. 📋 Poseida Therapeutics, Inc. (PSTX) - Regulatory Update Filing Date: 2022-06-16 Accepted: 2022-06-16 17:30:40 Event Type: Regulatory Update Event Details: Poseida Therapeutics (PSTX) Announces Regulatory Update Poseida Therapeutics (PSTX) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development: 🔬 Clinical Development Pipeline (Poseida Therapeutics, Inc.): Product Type Development Stage Therapeutic Area Source Rimiducid DRUG Phase PHASE1 Diffuse Large B-Cell Lymphoma, Not Otherwise Specified ClinicalTrials.gov P-CD19CD20-ALLO1 BIOLOGICAL Phase PHASE1 Diffuse Large B-Cell Lymphoma, Not Otherwise Specified ClinicalTrials.gov 💼 Business Developments: No business developments data available. Structured Data: Company Name: Poseida TherapeuticsCIK: 0001661460Ticker Symbol: PSTXPeriod End Date: 2022-06-16Document Type: 8-K
📋 Poseida Therapeutics, Inc. (PSTX) - Regulatory Update
Filing Date: 2022-06-16
Accepted: 2022-06-16 17:30:40
Event Type: Regulatory Update
Event Details:
🔬 Clinical Development Pipeline (Poseida Therapeutics, Inc.):
💼 Business Developments:
No business developments data available.
Structured Data: